NAMSA Acquires Syntactx

January 5, 2021

NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.

Buyers
NAMSA, ArchiMed
Targets
Syntactx
Sellers
Syntactx existing owners and management
Platforms
NAMSA
Location
New York, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.